| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/20/2001 | WO2001096375A2 33358, a novel human ankyrin family member and uses thereof |
| 12/20/2001 | WO2001096374A2 32252, a human amp-binding family member and uses thereof |
| 12/20/2001 | WO2001096372A2 Zinc transporters proteins and their use in medicinal preparations |
| 12/20/2001 | WO2001096370A2 Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
| 12/20/2001 | WO2001096369A1 Gluthione analogues and their use as antioxidants |
| 12/20/2001 | WO2001096368A2 Use of coiled-coil structural scaffold to generate structure-specific peptides |
| 12/20/2001 | WO2001096367A1 Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 12/20/2001 | WO2001096364A2 Peptides that stimulate cell survival and axon regeneration |
| 12/20/2001 | WO2001096362A1 A novel peptide --- human phosphatidase 16 and the polynucleotide coding this novel peptide |
| 12/20/2001 | WO2001096361A1 Method of controlling the binding of calmyrin to presenilin |
| 12/20/2001 | WO2001096360A1 Antisense modulation of c/ebp beta expression |
| 12/20/2001 | WO2001096359A1 Compositions, methods, and kits relating to resistin-like molecules |
| 12/20/2001 | WO2001096343A1 Substituted metal-phthalocyanines, their preparation and the use thereof |
| 12/20/2001 | WO2001096300A1 Growth hormone secretagogues |
| 12/20/2001 | WO2001096286A2 Urokinase inhibitors |
| 12/20/2001 | WO2001095951A1 Method of using lectins for contraception and prophylaxis agains t diseases transmittable by sexual contact and condom containing lectins |
| 12/20/2001 | WO2001095946A2 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | WO2001095943A2 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 12/20/2001 | WO2001095942A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001095931A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR |
| 12/20/2001 | WO2001095930A1 Method of photoreduction of hemoglobin vesicles |
| 12/20/2001 | WO2001095929A2 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095927A1 P43 anti-tumor therapeutic agent and three dimensional structure of its cytokine domain |
| 12/20/2001 | WO2001095926A1 Immunosuppressor agent derived from morbillivirus |
| 12/20/2001 | WO2001095925A1 Pharmaceutical anti-inflammatory aerosol formulation |
| 12/20/2001 | WO2001095924A2 Method for treating a movement disorder |
| 12/20/2001 | WO2001095919A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 12/20/2001 | WO2001095904A1 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| 12/20/2001 | WO2001095895A2 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
| 12/20/2001 | WO2001095885A1 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrin antagonist |
| 12/20/2001 | WO2001095882A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095874A2 Highly efficient delivery of a large therapeutic mass aerosol |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001095725A1 Biological control of pest animals |
| 12/20/2001 | WO2001095708A1 Vitamin d receptor-deficient cell line |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001085197A8 Method for curing diffusive masthopaty |
| 12/20/2001 | WO2001076620A3 Use of vegf and homologues to treat neuron disorders |
| 12/20/2001 | WO2001064751A3 High potency recombinant antibodies and method for producing them |
| 12/20/2001 | WO2001064164A3 Nanocapsule encapsulation system and method |
| 12/20/2001 | WO2001062933A3 Muteins of interleukin-13 (il-13) |
| 12/20/2001 | WO2001062267A3 Oral gel containing sulfurated amino acid compounds |
| 12/20/2001 | WO2001059100A3 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
| 12/20/2001 | WO2001057274A8 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart |
| 12/20/2001 | WO2001055725A3 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 12/20/2001 | WO2001055367A8 Nucleic acids, proteins, and antibodies |
| 12/20/2001 | WO2001055303A3 Nucleic acids, proteins, and antibodies |
| 12/20/2001 | WO2001054474A8 Nucleic acids, proteins, and antibodies |
| 12/20/2001 | WO2001052874A3 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 12/20/2001 | WO2001052835A3 Free radical scavengers for the treatment of premature birth |
| 12/20/2001 | WO2001051640A3 Regulation of human mitochondrial transformylase |
| 12/20/2001 | WO2001051073A3 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 12/20/2001 | WO2001048208A3 Streptococcus pyogenes virulence genes and proteins and their use |
| 12/20/2001 | WO2001044295A3 Agonists and antagonists of the receptor gpr19 and their use in appetite control |
| 12/20/2001 | WO2001040281A3 Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes |
| 12/20/2001 | WO2001031016A3 Processed human chemokines phc-1 and phc-2 |
| 12/20/2001 | WO2001023592A3 Methods for making recombinant proteins using apoptosis inhibitors |
| 12/20/2001 | WO2001010426A3 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 12/20/2001 | WO2000068387A3 Nucleic acids and proteins with interferon-beta activity |
| 12/20/2001 | WO2000067775A9 Fibroblast growth factor 15 |
| 12/20/2001 | WO2000060076A3 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 12/20/2001 | WO2000058358A9 49 human secreted proteins |
| 12/20/2001 | WO2000034309A9 Cloning and characterization of a cd2 binding protein (cd2bp2) |
| 12/20/2001 | WO2000024765A8 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/20/2001 | WO2000020593A9 Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof |
| 12/20/2001 | WO2000008133A9 NOVEL G PROTEIN-COUPLED RECEPTOR cDNA SEQUENCE |
| 12/20/2001 | WO1999063976A3 Liver-selective glucocorticoid antagonist for treating diabetes |
| 12/20/2001 | WO1998020029A3 Hnf3-delta compositions |
| 12/20/2001 | US20010053844 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/20/2001 | US20010053782 Pyrrolo[2,3-d]pyrimidine compounds |
| 12/20/2001 | US20010053770 Immunoreceptor tyrosine-based activation motif (ITAM); immunoreceptor tyrosine-based inhibition motif (ITIM); bispecific molecule such as fusion protein and vectors encoding it; treating allergic diseases |
| 12/20/2001 | US20010053769 Use of pro-apoptotic factors in treatment of atherosclerosis |
| 12/20/2001 | US20010053768 Gene therapy using replication competent targeted adenoviral vectors |
| 12/20/2001 | US20010053766 Administering a compound such as arginine-glycine-aspartic acid tripeptide that inhibits the interaction between integrin receptor and extracellular matrix to treat glaucoma or elevated intraocular pressure; drug screening |
| 12/20/2001 | US20010053765 Methods and compositions for the selective regulation of chorionic prostanoids |
| 12/20/2001 | US20010053764 Interleukin-1 inhibitors in the treatment of diseases |
| 12/20/2001 | US20010053762 Associated with failure of gamete maturation, by administering a complex comprising an insulin-like growth factor (IGF) and insulin-like growth factor binding protein-3 (IGFBP-3); male or female infertility |
| 12/20/2001 | US20010053761 Method for administering aspb28-human insulin |
| 12/20/2001 | US20010053760 Treatment of infarcts |
| 12/20/2001 | US20010053759 Skin cancer preventive agent |
| 12/20/2001 | US20010053548 Treating kidney tumors; administer human adjusted interferon, monitor tumor response to drugs |
| 12/20/2001 | US20010053539 Polypeptide for use in the diagnosis and treatment of blood, kidney and live disoders |
| 12/20/2001 | US20010053538 Biologically active synthetic thyrotropin and cloned gene for producing same |
| 12/20/2001 | US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor |
| 12/20/2001 | US20010053533 Detecting infectious protein in solution; prepare solution composed from body fluid or fluidized organ expose to chromatographic column, detect infectious protein |
| 12/20/2001 | US20010053532 Detecting agonist or antagonist of binding protein; incubation of agonist/antagonist with binding protein, monitor response from binding protein |
| 12/20/2001 | US20010053382 System and method for treating wounds, promoting healing and avoiding amputations in diabetic and non-diabetic patients |
| 12/20/2001 | US20010053381 Using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve the slowing, stopping or reversing of kidney disease |
| 12/20/2001 | US20010053380 System and method for treating heart disease and cardiovascular disease in diabetic and non-diabetic patients |
| 12/20/2001 | US20010053371 Molecule having an IL13-moiety and a cytotoxic moiety; especially for reducing growth of glioblastoma multiforme cells. |
| 12/20/2001 | US20010053370 Parkinson's disease treatment |
| 12/20/2001 | US20010053369 Treating a movement disorder by intracranial administration of a neurotoxin, especially a botulinium toxin |
| 12/20/2001 | US20010053366 Method of removing endotoxin from vaccines |
| 12/20/2001 | US20010053364 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion; relieving pain associated with smooth muscle disorders, including spasms in the sphincter muscles; type A & B toxins |
| 12/20/2001 | US20010053361 Immunotherapy involving cd28 stimulation |
| 12/20/2001 | US20010053360 Antibody binds an epitope on the HLA-DR polypeptide and induces apoptosis in cells expressing HLA-DR, without concomitant suppression of HLA-DR dependent immune responses. |
| 12/20/2001 | US20010053359 Intercellular Adhesion Molecule 1 (ICAM-1) and a bioadhesive |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |